Company: CMND
Filing Date: 2025-11-26
Form Type: F-1
Source: 0001213900-25-115501
Chunk: 32

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-26
Form: F-1
Chunk 32
---
 the same period, 4,894,456 warrants were exercised for gross proceeds of $5.3 million.

In addition to common shares, in the last three
years, we have granted (i) share options to employees, directors, consultants and service providers under our Executive Stock Option and
Restricted Share Unit Plans exercisable into an aggregate of 1,296,781 common shares, with exercise prices ranging from $23.40 to $642.03
per share; and (ii) an aggregate of 14,020,385 warrants exercisable into common shares, with exercise prices ranging from $0.20 to $243.75
per share, which were issued in three private placements.

Common Shares

All of our Common Shares are one and the same class,
identical in all respects and have equal rights, powers and privileges.

Voting.Except as otherwise provided for
by resolution of our Board, the holders of outstanding Common Shares have the exclusive right to vote on all matters requiring shareholder
action. On each matter on which holders of Common Shares are entitled to vote, each outstanding share of Common Share is entitled to one
vote.

Dividends.Holders of our Common Shares
have equal rights of participation in the dividends and other distributions of our cash, stock or property when, as and if declared thereon
by our Board from time to time out of our assets or funds legally available therefor and shall have equal rights to receive our assets
and funds available for distribution to shareholders in the event of any liquidation, dissolution or winding up of our affairs, whether
voluntary or involuntary.

Liquidation.Holders of our Common Shares
have equal rights to receive our assets and funds available for distribution to shareholders in the event of any liquidation, dissolution
or winding up of our affairs, whether voluntary or involuntary.

Rights and Preferences. Holders of our Common
Shares will have no preemptive, conversion or subscription rights, and there will be no redemption or sinking funds provisions applicable
to our Common Shares. The rights, preferences and privileges of the holders of our Common Shares will be subject to, and may be adversely
affected by, the rights of the holders of share of any series of our preferred stock that we may designate and issue in the future.

Fully Paid and Nonassessable. All of our
outstanding Common Shares are, and the Common Shares to be issued in this offering will be, fully paid and nonassessable.

<div align='center'>18</div>

Anti-T